217 related articles for article (PubMed ID: 23344002)
1. Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice.
Yamamoto T; Harada-Shiba M; Nakatani M; Wada S; Yasuhara H; Narukawa K; Sasaki K; Shibata MA; Torigoe H; Yamaoka T; Imanishi T; Obika S
Mol Ther Nucleic Acids; 2012 May; 1(5):e22. PubMed ID: 23344002
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates.
Lindholm MW; Elmén J; Fisker N; Hansen HF; Persson R; Møller MR; Rosenbohm C; Ørum H; Straarup EM; Koch T
Mol Ther; 2012 Feb; 20(2):376-81. PubMed ID: 22108858
[TBL] [Abstract][Full Text] [Related]
3. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
Gupta N; Fisker N; Asselin MC; Lindholm M; Rosenbohm C; Ørum H; Elmén J; Seidah NG; Straarup EM
PLoS One; 2010 May; 5(5):e10682. PubMed ID: 20498851
[TBL] [Abstract][Full Text] [Related]
4. Superior Silencing by 2',4'-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors.
Yamamoto T; Yasuhara H; Wada F; Harada-Shiba M; Imanishi T; Obika S
J Nucleic Acids; 2012; 2012():707323. PubMed ID: 23056920
[TBL] [Abstract][Full Text] [Related]
5. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.
Graham MJ; Lemonidis KM; Whipple CP; Subramaniam A; Monia BP; Crooke ST; Crooke RM
J Lipid Res; 2007 Apr; 48(4):763-7. PubMed ID: 17242417
[TBL] [Abstract][Full Text] [Related]
6. Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides.
Wada F; Yamamoto T; Kobayashi T; Tachibana K; Ito KR; Hamasaki M; Kayaba Y; Terada C; Yamayoshi A; Obika S; Harada-Shiba M
Mol Ther Nucleic Acids; 2021 Dec; 26():957-969. PubMed ID: 34760338
[TBL] [Abstract][Full Text] [Related]
7. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
8. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
[TBL] [Abstract][Full Text] [Related]
9. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
[TBL] [Abstract][Full Text] [Related]
10. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
[TBL] [Abstract][Full Text] [Related]
11. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
12. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia.
Wu C; Xi C; Tong J; Zhao J; Jiang H; Wang J; Wang Y; Liu H
Acta Pharm Sin B; 2019 Nov; 9(6):1216-1230. PubMed ID: 31867167
[TBL] [Abstract][Full Text] [Related]
14. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
15. Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma.
Yamamoto T; Obika S; Nakatani M; Yasuhara H; Wada F; Shibata E; Shibata MA; Harada-Shiba M
Eur J Pharmacol; 2014 Jan; 723():353-9. PubMed ID: 24269597
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis.
Momtazi-Borojeni AA; Jaafari MR; Badiee A; Banach M; Sahebkar A
BMC Med; 2019 Dec; 17(1):223. PubMed ID: 31818299
[TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
18. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
19. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
20. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
